Matrixmetalloproteinases (MMPs) belong to family of proteolytic enzymes that cause degradation of extracellular matrix macromolecules,
including interstitial and basement membrane collagens, fibronectin, laminin and proteoglycan core protein by secreting enzymes in latent form;
which later gets activated in the pericellular environment by disruption of a Zn++ cysteine bond. There is much evidence for the role of matrix
metalloproteinases in the destructive processes of periodontal disease distinguishing them as a viable target for a chemotherapeutic approach.
The use of a host modulatory agent such as a matrix metalloproteinase inhibitor can assist with conventional treatment for periodontitis and,
when used adjunctively, can enhance and make clinical therapeutic responses more predictable in the more susceptible patient.